|
(Health-NewsWire.Net, July 21, 2015 ) Contraception - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Contraception - Pipeline Review, H1 2015” which provides an overview of the Women's Health therapeutics pipeline.
This report gives extensive data on the remedial advancement for Contraception, complete with relative examination at different stages, therapeutics appraisal by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It additionally audits key players included in the remedial improvement for Contraception and exceptional components on late-stage and suspended tasks.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H1, 2015 Pipeline Review of “Psoriatic Arthritis” addition with 33 market data tables and 16 figures, spread across 87 pages is http://www.rnrmarketresearch.com/contraception-pipeline-review-h1-2015-market-report.html .
This report highlights investigational medications from crosswise over globe covering more than 20 treatment regions and about 3,000 signs. The report is assembled utilizing information and data sourced from databases, Company/University sites, SEC filings, speculator presentations and included press discharges from organization/college locales and industry-particular outsider sources, set up together by Global Markets Direct's group. Medication profiles/records included in the report experiences intermittent updation taking after a stringent arrangement of procedures that guarantees that every one of the profiles are overhauled with the most recent arrangement of data. Moreover, procedures including live news & arrangements following, program based ready box and clinical trials registries following guarantee that the latest improvements are caught on a continuous premise.
Drugs Profile Discussed in this Research :
(ethinyl estradiol + levonorgestrel), (ethinylestradiol + levonorgestrel), (nestorone + estradiol), (prasterone + estradiol + progesterone), AG-200 ER, AG-200 SP, Amphora, esterol, etonogestrel, EVE-106, levonorgestrel, LJ-102, MK-8342B, Monoclonal Antibody Conjugates for Contraception, norethindrone, S-003296, S-0101255, Small Molecule 1 for Fertility Control, Small Molecule 2 for Fertility Control, Small Molecule to Modulate Progesterone Receptor for Fertility Control, Small Molecules to Block CatSper1 Ion Channel for Contraception, Synthetic Peptides for Contraception, tanaproget and ulipristal acetate
Companies Discussed/Mentioned in this Research:
Actavis plc, Agile Therapeutics, Inc., ANI Pharmaceuticals, Inc., Antares Pharma, Inc., Evofem, Inc., Hydra Biosciences, Inc., Intas Pharmaceuticals Ltd., Ligand Pharmaceuticals, Inc., Merck & Co., Inc., Orbis Biosciences, Inc., Pantarhei Bioscience BV and Teva Pharmaceutical Industries Limited
Inquire for discount on this report http://www.rnrmarketresearch.com/contacts/discount?rname=394574 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Contraception
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Contraception
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Women's Health therapeutics Market
If you look at the anatomy of the female physiology then there are a lot of complexities in its creation. This is in fact considered to be the sole reason why women tend to be more conscious about their health. Leading therapeutic segments of the health care market have aimed this sector to welcome faster success but ignorance has not being able to give the market of Women�s Health therapeutics its own pinnacle.
Since the dominance of the market has being shifted from the brands to new competitors, people do welcome it but with a small trifle in their minds. Now if the therapists do not intervene to introduce them to the suitable patients then there is surely a big concern to be taken immediately. It has been surveyed that incorrect treatment usage patterns can at times really make it tough to forecast any positive change in annual cost of therapy. Postmenopausal osteoporosis and menopause are some of the dominant issues.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
